Program 03 Prostate Cancer

计划 03 前列腺癌

基本信息

批准号：
10332548
负责人：
Steven P. Balk
金额：
$ 4.18万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-03-10 至 2026-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10332548
关键词：
AR gene Acetates Address African American Androgen Receptor Androgens Armenia Attention Biological Models Biological Process Biostatistics Core CDK4 gene Cancer Center Cancer Center Support Grant Cancer Patient Castration Catchment Area Cells ChIP-seq Clinical Clinical Investigator Clinical Trials Collaborations Community Outreach Data Data Science Detection Development Direct Costs Early treatment Elements Enhancers Epigenetic Process Funding Genes Genets Institution International Length Link Malignant Neoplasms Malignant neoplasm of prostate Massachusetts Mediating Mission Mutate Mutation Nature Neoadjuvant Therapy Neoplasm Metastasis Nonmetastatic PD-1 blockade Paper Patients Peer Review Grants Phenotype Prostate Publishing RNA Splicing Reporting Research Research Design Research Personnel Resistance Resource Sharing Resources Sampling Series Signal Transduction Structure Surrogate Endpoint Training Tumor Suppressor Genes Upstream Enhancer Variant abiraterone androgen deprivation therapy antagonist biomarker-driven cancer biomarkers cancer cell cancer epidemiology cancer genetics castration resistant prostate cancer clinical practice clinical translation collaborative trial community engagement enzalutamide exome sequencing gene repression genome sequencing genome wide association study genome-wide genomic biomarker improved improved outcome in vivo inhibitor inter-institutional member men multidisciplinary next generation novel patient population phase II trial phase III trial programmed cell death ligand 1 programs prostate cancer risk resistance mechanism risk stratification transcriptome tumor tumor progression whole genome

项目摘要

Prostate Cancer Program Project Summary / Abstract The Prostate Cancer Program seeks to improve outcomes for all prostate cancer patients by bringing together a multidisciplinary team of investigators across the DF/HCC consortium to catalyze and accelerate research leading to clinical benefit. A founding premise of the Program is that genuine progress in the management of prostate cancer requires iterative fundamental discovery through research in model systems and in patient- derived samples, clinical translation, and subsequent analysis of patient-derived clinical samples to assess mechanisms of action and sensitivity or resistance in vivo. The Program harnesses CCSG structures and resources to achieve this iterative cycle. Additionally, the Program addresses the diversity of our catchment area (Massachusetts) and pays particular attention to training the next generation of basic and clinical investigators across the consortium. The Program’s 66 members (42 primary and 24 secondary) represent seven DF/HCC institutions and 11 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $2.6 million in direct costs from the NCI and $3.4 million from other sponsors. During the current funding period, primary Program members published 840 cancer-relevant papers. Of these, 27% were inter-institutional, 30% were intra-programmatic, and 31% were inter-programmatic collaborations between two or more DF/HCC members. To achieve the Program mission, our Specific Aims for the next CCSG funding period are to 1) Improve detection and early treatment of aggressive prostate cancer; 2) Identify mechanisms of resistance to current therapies and identify further targetable vulnerabilities; and 3) Exploit tumor specific vulnerabilities through biomarker driven clinical trials that include diverse patient populations. The disproportionate burden of prostate cancer on African American men underlies key elements of each Aim, which therefore depend in part on the Community Outreach and Engagement (COE) functions of the Cancer Center. In addition, Program members rely heavily on Center collaborative and clinical trials structures and shared resources.

前列腺癌计划项目概要/摘要前列腺癌计划旨在通过聚集在一起来改善所有前列腺癌患者的治疗结果 DF/HCC 联盟的多学科研究人员团队致力于促进和加速研究该计划的一个创立前提是管理方面的真正进展。前列腺癌需要通过模型系统和患者研究进行迭代的基础发现衍生样本、临床翻译以及随后对患者衍生临床样本进行分析以评估该程序利用 CCSG 结构和体内作用机制和敏感性或耐药性。此外，该计划还解决了我们流域的多样性问题。地区（马萨诸塞州）并特别注重培养下一代基础和临床整个财团的调查员。该计划的 66 名成员（42 名小学和 24 名中学）代表 7 家 DF/HCC 机构和 11 家 2019 年，该计划经同行评审的资助金额为 260 万美元。 NCI 的直接费用和其他赞助商提供的 340 万美元在当前资助期间，主要费用。项目成员发表了 840 篇癌症相关论文，其中 27% 是跨机构论文，30% 是跨机构论文。项目内合作，31% 是两个或多个 DF/HCC 成员之间的项目间合作。为了实现该计划的使命，我们下一个 CCSG 资助期的具体目标是 1) 改进侵袭性前列腺癌的检测和早期治疗；2) 确定耐药机制；当前的治疗方法并进一步识别可针对的漏洞；3）利用肿瘤特定的漏洞通过生物标志物驱动的临床试验，包括不同的患者群体。非洲裔美国男性前列腺癌的发病率是每个目标的关键要素的基础，因此取决于此外，癌症中心的社区外展和参与 (COE) 职能的一部分。计划成员严重依赖中心协作和临床试验结构以及共享资源。